Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety

0
0 / 5 (0 votos)

European Journal of Hematology

Fecha de publicación: 20 october 2018

DOI: https://doi.org/10.1111/ejh.13186

Autores: Reyad Dada, Binyam Usman

Background: Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment‐sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some concerns around performing such procedure after checkpoint inhibitors (CPIs).

Seguir leyendo